Added daily report
This commit is contained in:
Navan Chauhan
parent
13fc0fa8e1
commit
c61980994f
|
|
@ -0,0 +1,202 @@
|
|||
<!DOCTYPE html>
|
||||
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
||||
<meta charset="utf-8"/>
|
||||
<meta content="pandoc" name="generator"/>
|
||||
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
||||
<title>05 November, 2021</title>
|
||||
<style type="text/css">
|
||||
code{white-space: pre-wrap;}
|
||||
span.smallcaps{font-variant: small-caps;}
|
||||
span.underline{text-decoration: underline;}
|
||||
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
||||
</style>
|
||||
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
||||
<body>
|
||||
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
||||
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
||||
<ul>
|
||||
<li><a href="#from-preprints">From Preprints</a></li>
|
||||
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
||||
<li><a href="#from-pubmed">From PubMed</a></li>
|
||||
<li><a href="#from-patent-search">From Patent Search</a></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
||||
<ul>
|
||||
<li><strong>Moralizing the COVID-19 Pandemic: Self-Interest Predicts Moral Condemnation of Other’s Compliance, Distancing and Vaccination</strong> -
|
||||
<div>
|
||||
The emergence of the novel coronavirus has put societies under tremendous pressure to instigate massive and rapid behavior change. Throughout history, an effective strategy to facilitate novel behaviors has been to morally condemn those who do not behave in an appropriate way. Accordingly, here, we investigate if complying with the advice of health authorities—e.g. to physically distance or vaccinate—has emerged as a moralized issue during the COVID-19 pandemic. In Study 1, we rely on data (N = 94K) from quota-sampled rolling cross-sectional online surveys from eight countries (Denmark, Sweden, Germany, France, Italy, Hungary, the UK, and the US). We find that large majorities find it justified to condemn those who do not keep a distance to others in public and around half of respondents blame ordinary citizens for the severity of the pandemic. Furthermore, we identify the most important predictors of condemnation to be behavior change and personal concern, while institutional trust and social distrust also play large but less consistent roles. Study 2 offers a registered replication of our findings on a representative sample of Britons (N = 1.5K). It shows that both moralization and condemnation of both vaccination and general compliance are best predicted by self-interested considerations.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://psyarxiv.com/3rczg/" target="_blank">Moralizing the COVID-19 Pandemic: Self-Interest Predicts Moral Condemnation of Other’s Compliance, Distancing and Vaccination</a>
|
||||
</div></li>
|
||||
<li><strong>Health behaviors and mental health before and during the COVID-19 pandemic: A longitudinal population-based survey</strong> -
|
||||
<div>
|
||||
Background: Health behaviors such as physical activity and a balanced diet are essential to promote and maintain health. Especially during a crisis, such as the COVID-19 pandemic, they have the potential to buffer against stress and protect mental health. Method: In a longitudinal study with four measurement points over 3 months during the COVID-19 pandemic, about 3,500 randomly selected participants representative of the German population reported their mental health (i.e., anxiety, depression, loneliness), screen time, snack consumption, and physical activity. Results: Symptoms of anxiety, depression, and loneliness were highest during the first month of the pandemic-related lockdown, particularly in women and people in poor health, and decreased over time. Screen time and snacking increased and physical activity decreased compared to pre-lockdown. Snacking and physical activity went back to pre-lockdown levels within 2 months; screen time increased further over time. Snack increase and physical activity decrease was stronger in women than men throughout the lockdown. Generally, more screen time, more snacking, and less physical activity were related to higher symptoms of anxiety, depression, and loneliness across all time points. Changes in health behaviors over time did not predict changes in mental health symptoms. Conclusions: Mental health and health behaviors worsened as an immediate response to stress but mostly returned to pre-crisis levels within 2 to 3 months. Engaging in healthier behaviors is associated with better mental health. This study provides important descriptions of (unintended) side effects of a national crisis and contributes to our understanding of how to preserve mental health.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://psyarxiv.com/qbgh7/" target="_blank">Health behaviors and mental health before and during the COVID-19 pandemic: A longitudinal population-based survey</a>
|
||||
</div></li>
|
||||
<li><strong>Increase of depressive symptoms among adolescents during the first COVID-19 lockdown in Germany - results from a German panel study</strong> -
|
||||
<div>
|
||||
Background The COVID-19 pandemic has fundamentally changed social life within a very short time. Lockdown policies often consider the trade-off between containing the spread of the pandemic and the negative impact for the economy. Policy makers should pay more attention to the psychological and social impacts of the lockdown. Objectives How did the mental health of adolescents in Germany change during the first wave of the COVID-19 pandemic and the lockdown in Germany? Material and Methods Analyses are based on longitudinal data from Germany and a random sample of the birth cohorts 2001-03. Respondents were 15-17 years old at the first interview in 2018/19. 854 adolescents participated in the second wave of the survey in May and June 2020. Depressiveness is assessed with the State-Trait Depression Scale. Results During the first lockdown, adolescents show a significant increase in depressive symptoms. Prior to the lockdown, 10.2 percent had clinically relevant depressive symptoms [CI: 8.0; 12.4]. In spring 2020, the prevalence increased to 25.2 percent [CI: 22.0; 28.4]. Young women have a significantly higher risk of developing depressive symptoms than men of the same age. Immigrant background is an equally strong risk factor. The prevalence of depressive symptoms among adolescents with an immigrant background increased from 11% to 33%. Discussion To address this increased mental health risk and the inequalities, policy makers and society should ensure access and availability of target- group-specific and low-threshold prevention and counselling.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://psyarxiv.com/pfqeg/" target="_blank">Increase of depressive symptoms among adolescents during the first COVID-19 lockdown in Germany - results from a German panel study</a>
|
||||
</div></li>
|
||||
<li><strong>SARS-CoV-2 Aerosol Transmission Indoors: A Closer Look at Viral Load, Infectivity, the Effectiveness of Preventive Measures and a Simple Approach for Practical Recommendations</strong> -
|
||||
<div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Currently, airborne transmission is seen as the most important transmission path for SARS-CoV-2. In this investigation, a classic dose-response model is used on the one hand to find out retrospectively the probable viral load of the infectious source patient at the time of transmission in 25 documented outbreaks. We showed that an infection due to airborne transmission at a distance from the infectious person was probably only possible in the 25 outbreaks examined, with attack rates of 4-100%, if the viral load had been higher than 1E+08 viral copies/ml. This demonstrates that the viral load estimated from the swab might overestimate a person9s infectivity via aerosol, because a person is generally considered infectious, independent of the transmission way, when the viral load from the swab is 1E+06 viral copies/ml. On the other hand, a possible approach is presented to predict the probable situational Attack Rate (PARs) of a group of persons in a room through aerosol particles emitted by an infectious source patient. Four main categories of influence on the risk of infection are formed: First the emitted viruses, depending on the viral load and the amount of respiratory particles, and necessary number of reproducible viruses for infection, second the room-specific data and duration of stay of the group of people, third the activity of the exposed persons, and fourth the effect of personal protection (e.g. wearing masks from infectious and/or susceptible person). Furthermore, a simplified method is presented to calculate either the maximum possible number of persons in a room, so that probably a maximum of one person becomes infected when an infectious person is in the room, or the PARs,simple for a given number of persons, ventilation rate and time of occupancy. We additionally show, taking into account organizational preventive measures, which person-related virus-free supply air flow rates are necessary to keep the number of newly infected persons to less than 1. The simple approach makes it easy to derive preventive organizational and ventilation measures. Our results show that the volume flow rate or a person-related flow rate is a much more effective parameter to evaluate ventilation for infection prevention than the air change rate. We suggest to monitor the CO2 concentration as an easy to implement and valid measurement system for indoor spaces. Finally, we show that of the three measures, besides of wearing masks and increasing ventilation, testing contributes the most to the joint protective effect. This corresponds to the classic approach to implement protection concepts: preventing the source from entering the room and emitting viruses at all. In summary, a layered approach of different measures is recommended to mutually compensate for possible failures of any one measure (e.g. incorrect execution of tests, incorrect fit of masks or irregular window opening), to increase the degree of protection and thus reduce the risk of transmission of SARS-CoV-2.
|
||||
</p>
|
||||
</div>
|
||||
<div class="article- link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.11.04.21265910v1" target="_blank">SARS-CoV-2 Aerosol Transmission Indoors: A Closer Look at Viral Load, Infectivity, the Effectiveness of Preventive Measures and a Simple Approach for Practical Recommendations</a>
|
||||
</div></li>
|
||||
<li><strong>Of masks and methylene blue - the use of methylene blue photochemical treatment to decontaminate surgical masks contaminated with a tenacious small non-enveloped norovirus</strong> -
|
||||
<div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Background In the context of the SARS-CoV-2 pandemic, reuse of personal protective equipment, specifically that of medical face coverings, has been recommended. The reuse of these typically single-use only items necessitates procedures to inactivate contaminating human respiratory and gastrointestinal pathogens. We previously demonstrated decontamination of surgical masks and respirators contaminated with infectious SARS-CoV-2 and various animal coronaviruses via low concentration- and short exposure methylene blue photochemical treatment (10 uM methylene blue, 30 minutes of 12,500-lux red light or 50,000 lux white light exposure). Methods Here, we describe the adaptation of this protocol to the decontamination of a more resistant, non-enveloped gastrointestinal virus and demonstrate efficient photodynamic inactivation of murine norovirus, a human norovirus surrogate. Results Methylene blue photochemical treatment (100 uM methylene blue, 30 minutes of 12,500-lux red light exposure) of murine norovirus-contaminated masks reduced infectious viral titres by over four orders of magnitude on surgical mask surfaces. Discussion and Conclusions Inactivation of a norovirus, the most difficult to inactivate of the respiratory and gastrointestinal human viruses, can predict the inactivation of any less resistant viral mask contaminant. The protocol developed here thus solidifies the position of methylene blue photochemical decontamination as an important tool in the package of practical pandemic preparedness.
|
||||
</p>
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.11.04.21265909v1" target="_blank">Of masks and methylene blue - the use of methylene blue photochemical treatment to decontaminate surgical masks contaminated with a tenacious small non- enveloped norovirus</a>
|
||||
</div></li>
|
||||
<li><strong>Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies</strong> -
|
||||
<div>
|
||||
Neutralizing antibodies (nAbs) that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (S-protein) are promising therapeutics for COVID-19. However, natural bivalent nAbs suffer from limited potency and are vulnerable to SARS-CoV-2 variants with mutated RBDs. We report a novel format that enables modular assembly of bi- paratopic, tetravalent nAbs with antigen-binding sites from two distinct nAbs. The diabody-Fc-Fab format consists of a central Fc with a bivalent diabody fused to its N-terminus and two Fabs fused to its C-terminus. The diabody and Fab modules do not interfere with each other, and thus, any diabody can be combined with any Fab in a facile manner. We engineered a diabody-Fc-Fab that contained the paratopes of two distinct nAbs derived from a phage-displayed library of synthetic Abs. The tetravalent nAb was purified in high yields with methods used to produce conventional IgGs, and it exhibited favorable biophysical characteristics comparable to those of approved therapeutic antibodies. The tetravalent nAb bound to the S-protein trimer at least 100-fold more tightly than the bivalent IgGs (apparent KD <1 pM). Most importantly, the tetravalent nAb exhibited extremely high potencies in neutralization assays across a panel of pseudoviruses representing seven natural SARS-CoV-2 variants (IC50 <5 ng/mL), including several that resisted IgGs and are known to evade approved IgG drugs. Taken together, our results showed that the tetravalent diabody-Fc-Fab is a robust, modular platform for rapid production of drug-grade nAbs with potencies and breadth of coverage that far exceed those of conventional bivalent IgGs.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.11.02.466984v1" target="_blank">Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies</a>
|
||||
</div></li>
|
||||
<li><strong>Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults</strong> -
|
||||
<div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
In light of intermittent supply shortages of individual vaccines and evidence of rare but serious adverse events after vaccination, heterologous regimens for COVID-19 vaccines have gained significant interest. This study aims to assess the reactogenicity and immunogenicity of the heterologous adenoviral vector vaccine regimen (ChAdOx1-S, AstraZeneca; hereafter referred to as AZ) and the inactivated vaccine regimen (CoronaVac; hereafter referred to as CV) regimen in healthy Thai adults immunized between June and September 2021. Our study showed that adverse events following homologous CV-CV and AZ-AZ, and heterologous CV-AZ and AZ-CV combinations, were mild and well tolerated overall. Receptor-binding domain (RBD)-specific antibody responses and neutralizing activities against wild-type and variants of concern after two-dose vaccination were higher in the heterologous CV-AZ and homologous AZ-AZ groups compared to the CV- CV and AZ-CV groups. Conversely, the spike-specific IgA response was detected only in the CV-AZ group after two doses of vaccination. The total interferon gamma response was detected in both the CV-AZ and AZ-CV groups after the two-dose vaccination. Given the shorter completion time of two doses, heterologous CoronaVac followed by ChAdOx1-S can be considered as an alternative regimen to homologous efficacy-proven ChAdOx1-S in countries with circulating variants. Additional studies on the efficacy and durability of immune responses induced by heterologous vaccine regimens are warranted.
|
||||
</p>
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.11.04.21265908v1" target="_blank">Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults</a>
|
||||
</div></li>
|
||||
<li><strong>Estimation of the basic reproduction number of COVID-19 from the incubation period distribution</strong> -
|
||||
<div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Background The estimates of future course of spreading of the SARS-CoV-2 virus are frequently based on Markovian models in which the transitions between the compartments are exponentially distributed. Specifically, the basic reproduction number R0 is also determined from formulae where it is related to the parameters of such models. The observations show that the start of infectivity of an individual appears nearly at the same time as the onset of symptoms, while the distribution of the incubation period is not an exponential. Methods We propose a method for estimation of R0 for COVID-19 based on the empirical incubation period distribution and assumed very short infectivity period that lasts only few days around the onset of symptoms. It is tested on daily new cases in six major countries in Europe, in the first wave of epidemic in spring, 2020. Results The calculations show that even if the infectivity starts two days before the onset of symptoms and stops immediately when they appear, the value of R0 is larger than that from the classical, Markovian approach. For more realistic cases, when only individuals with mild symptoms spread the virus for few days after onset of symptoms, the respective values are even larger. Conclusions The calculations of R0 and other characteristics of spreading of COVID-19 based on the classical, Markovian approaches should be taken very cautiously. Instead, non-Markovian models with general distribution functions of transition between compartments should be considered as more appropriate.
|
||||
</p>
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.11.04.21265937v1" target="_blank">Estimation of the basic reproduction number of COVID-19 from the incubation period distribution</a>
|
||||
</div></li>
|
||||
<li><strong>Severity and inpatient mortality of COVID-19 pneumonia from Beta variant infection: a clinical cohort study in Cape Town, South Africa</strong> -
|
||||
<div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Background The SARS-CoV-2 Beta variant, associated with immune escape and higher transmissibility, drove a more severe second COVID-19 wave in South Africa. Individual patient level characteristics and outcomes with the Beta variant are not well characterized. Methods We performed a retrospective cohort study comparing disease severity and inpatient mortality of COVID-19 pneumonia between the first and second wave periods at a referral hospital in Cape Town, South Africa. Beta variant infection was confirmed by genomic sequencing. Outcomes were analyzed with logistic regression and accelerated failure time models. Results 1,182 patients were included: 571 during the first wave period and 611 from the second wave. Beta variant accounted for 97% of infections in the second wave. There was no difference in crude in- hospital mortality between wave periods (first wave 22.2%, second wave 22.1%; p = 0.9). Time to death was decreased with higher weekly hospital admissions (16%; 95% CI, 8 to 24 for every 50-patient increase), age (18%; 95% CI, 12 to 24 for every 10-year increase) and hypertension (31%; 95% CI, 12 to 46). Corticosteroid use delayed time to death by 2-fold (95% CI, 1.5 to 3.0). Admission during the second wave decreased time to death after adjustment for other predictors, but this did not reach statistical significance (24%; 95% CI, 47 to -2). There was no effect of HIV on survival. Conclusions There was a trend towards earlier mortality during the second COVID-19 wave driven by the Beta variant, suggesting a possible biological basis. Use of oral prednisone was strongly protective.
|
||||
</p>
|
||||
</div>
|
||||
<div class="article- link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.11.04.21265916v1" target="_blank">Severity and inpatient mortality of COVID-19 pneumonia from Beta variant infection: a clinical cohort study in Cape Town, South Africa</a>
|
||||
</div></li>
|
||||
<li><strong>Coronavirus RNA synthesis takes place within membrane-bound sites</strong> -
|
||||
<div>
|
||||
Infectious bronchitis virus (IBV), a gammacoronavirus, is an economically important virus to the poultry industry as well as a significant welfare issue for chickens. As for all positive strand RNA viruses, IBV infection causes rearrangements of the host cell intracellular membranes to form replication organelles. Replication organelle formation is a highly conserved and vital step in the viral life cycle. Here, we investigate the localization of viral RNA synthesis and the link with replication organelles in host cells. We have shown that sites of viral RNA synthesis and virus-related dsRNA are associated with one another and, significantly, that they are located within a membrane-bound compartment within the cell. We have also shown that some viral RNA produced early in infection remains within these membranes throughout infection. Importantly, we demonstrate conservation across all four coronavirus genera, including SARS-CoV-2. Under-standing more about the replication of these viruses is imperative in order to effectively find ways to control them.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.11.04.467246v1" target="_blank">Coronavirus RNA synthesis takes place within membrane-bound sites</a>
|
||||
</div></li>
|
||||
<li><strong>Marked enhancement of neutralizing antibody and IFN-γ T-cell responses by GX-19N DNA booster in mice primed with inactivated vaccine</strong> -
|
||||
<div>
|
||||
In response to the COVID-19 pandemic, an unprecedented level of vaccine development has occurred. As a result, various COVID-19 vaccines have been approved for use. Among these, inactivated virus particle vaccines have been widely used worldwide, but additional vaccination strategies are needed because of the short duration of immune responses elicited by these vaccines. Here, we evaluated homologous and heterologous prime-boost regimens using inactivated virus particle vaccine and GX-19N DNA vaccine for their ability to enhance the protective immune response against SARS-CoV-2. We demonstrated that a heterologous prime-boost regimen with the inactivated virus particle vaccine and GX-19N DNA vaccine resulted in enhanced SRBD- and N-specific antibody responses, compared to the homologous inactivated virus particle vaccine prime-boost vaccination. In addition, the neutralizing antibody response was significantly improved with the heterologous inactivated virus particle prime DNA boost regimen, and the neutralizing antibody induced with the heterologous prime boost regimen did not decrease against the SARS-CoV-2 variant of concern. The heterologous inactivated virus particle prime-DNA boost regimen not only significantly increased S- and N-specific IFN-g T cell responses, but also induced an equivalent level of T cell response against SARS-CoV-2 variant of concerns. Our results provide new insights into prophylactic vaccination strategies for COVID-19 vaccination.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.11.02.467026v1" target="_blank">Marked enhancement of neutralizing antibody and IFN-γ T-cell responses by GX-19N DNA booster in mice primed with inactivated vaccine</a>
|
||||
</div></li>
|
||||
<li><strong>Protein arginylation is regulated during SARS-CoV-2 infection</strong> -
|
||||
<div>
|
||||
In 2019, the world witnessed the onset of an unprecedented pandemic. In September 2021, the infection by SARS-CoV-2 had already been responsible for the death of more than 4 million people worldwide. Recently, we and other groups discovered that SARS-CoV-2 infection induces ER-stress and activation of unfolded protein response (UPR) pathway. The degradation of misfolded/unfolded proteins is an essential element of proteostasis and occurs mainly in lysosomes or proteasomes. The N-terminal arginylation of proteins is characterized as an inducer of ubiquitination and proteasomal degradation by the N-end rule pathway. Here we present, for the first time, data on the role of arginylation during SARS-CoV-2 infection. We studied the modulation of protein arginylation in Vero CCL-81 and Calu-3 cells infected after 2h, 6h, 12h, 24h, and 48h. A reanalysis of in vivo and in vitro public omics data combined with immunoblotting was performed to measure the levels of ATE1 and arginylated proteins. This regulation is seen specifically during infections by coronaviruses. We demonstrate that during SARS-CoV-2 infection there is an increase in the expression of the ATE1 enzyme associated with regulated levels of specific arginylated proteins. On the other hand, infected macrophages showed no ATE1 regulation. An important finding revealed that modulation of the N-end rule pathway differs between different types of infected cells. We also confirmed the potential of tannic acid to reduce viral load, and furthermore, to modulate ATE1 levels during infection. In addition, the arginylation inhibitor merbromin (MER) is also capable of both reducing viral load and reducing ATE1 levels. Taken together, these data show the importance of arginylation during the progression of SARS-CoV-2 infection and open the door for future studies that may unravel the role of ATE1 and its inhibitors in pathogen infection.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.11.02.466971v1" target="_blank">Protein arginylation is regulated during SARS-CoV-2 infection</a>
|
||||
</div></li>
|
||||
<li><strong>Comparing protein-protein interaction networks of SARS-CoV-2 and (H1N1) influenza using topological features</strong> -
|
||||
<div>
|
||||
Background: SARS-CoV-2 pandemic first emerged in late 2019 in China. It has since infected more than 183 million individuals and caused about 4 million deaths globally. A protein-protein interaction network (PPIN) and its analysis can provide insight into the behavior of cells and lead to advance the procedure of drug discovery. The identification of essential proteins is crucial to understand for cellular survival. There are many centrality measures to detect influential nodes in complex networks. Since SARS-CoV-2 and (H1N1) influenza PPINs pose 553 common proteins. Analyzing influential proteins and comparing these networks together can be an effective step helping biologists in drug design. Results: We used 21 centrality measures on SARS-CoV-2 and (H1N1) influenza PPINs to identify essential proteins. PCA- based dimensionality reduction was applied on normalized centrality values. Some measures demonstrated a high level of contribution in comparison to others in both PPINs, like Barycenter, Decay, Diffusion degree, Closeness (Freeman), Closeness (Latora), Lin, Radiality, and Residual. Using validation measures, the appropriate clustering method was chosen for centrality measures. We also investigated some graph theory-based properties like the power law, exponential distribution, and robustness. Conclusions: Through analysis and comparison, both networks exhibited remarkable experimental results. The network diameters were equal and in terms of heterogeneity, SARS-CoV-2 PPIN tends to be more heterogeneous. Both networks under study display a typical power-law degree distribution. Dimensionality reduction and unsupervised learning methods were so effective to reveal appropriate centrality measures.
|
||||
</div>
|
||||
<div class="article- link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.11.02.463717v1" target="_blank">Comparing protein-protein interaction networks of SARS-CoV-2 and (H1N1) influenza using topological features</a>
|
||||
</div></li>
|
||||
<li><strong>Clinically observed deletions in SARS-CoV-2 Nsp1 affect protein stability and its ability to inhibit translation</strong> -
|
||||
<div>
|
||||
Nonstructural protein 1 (Nsp1) is a major pathogenicity factor of SARS-CoV-2. It inhibits host-cell translation, primarily through a direct interaction between its C-terminal domain and the mRNA entry channel of the 40S small ribosomal subunit, with an N-terminal {beta}-barrel domain fine-tuning the inhibition and promoting selective translation of viral mRNA. SARS-CoV-2 nsp1 is a target of recurring deletions, some of which are associated with altered COVID-19 disease progression. To provide the biochemical basis for this, it is essential to characterize the efficiency of translational inhibition by the said protein variants. Here, we use an in vitro translation system to investigate the translation inhibition capacity of a series of clinically observed Nsp1 deletion variants. We find that a frequently observed deletion of residues 79-89 destabilized the N-terminal domain (NTD) and severely reduced the capacity of Nsp1 to inhibit translation. Interestingly, shorter deletions in the same region have been reported to effect the type I interferon response but did not affect translation inhibition, indicating a possible translation-independent role of the Nsp1 NTD in interferon response modulation. Taken together, our data provide a mechanistic basis for understanding how deletions in Nsp1 influence SARS-CoV-2 induction of interferon response and COVID-19 progression.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.11.03.467065v1" target="_blank">Clinically observed deletions in SARS-CoV-2 Nsp1 affect protein stability and its ability to inhibit translation</a>
|
||||
</div></li>
|
||||
<li><strong>Deep phylogenetic-based clustering analysis uncovers new and shared mutations in SARS-CoV-2 variants as a result of directional and convergent evolution</strong> -
|
||||
<div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Nearly two decades after the last epidemic caused by a severe acute respiratory syndrome coronavirus (SARS-CoV), newly emerged SARS-CoV-2 quickly spread in 2020 and precipitated an ongoing global public health crisis. Both the continuous accumulation of point mutations, owed to the naturally imposed genomic plasticity of SARS-CoV-2 evolutionary processes, as well as viral spread over time, allow this RNA virus to gain new genetic identities, spawn novel variants and enhance its potential for immune evasion. Here, through an in-depth phylogenetic clustering analysis of upwards of 200,000 whole-genome sequences, we reveal the presence of not previously reported and hitherto unidentified mutations and recombination breakpoints in Variants of Concern (VOC) and Variants of Interest (VOI) from Brazil, India (Beta, Eta and Kappa) and the USA (Beta, Eta and Lambda). Additionally, we identify sites with shared mutations under directional evolution in the SARS-CoV-2 Spike-encoding protein of VOC and VOI, tracing a heretofore-undescribed correlation with viral spread in South America, India and the USA. Our evidence-based analysis provides well-supported evidence of similar pathways of evolution for such mutations in all SARS-CoV-2 variants and sub-lineages. This raises two pivotal points: the co-circulation of variants and sub-lineages in close evolutionary environments, which sheds light onto their trajectories into convergent and directional evolution (i), and a linear perspective into the prospective vaccine efficacy against different SARS-CoV-2 strains (ii).
|
||||
</p>
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.10.14.21264474v2" target="_blank">Deep phylogenetic-based clustering analysis uncovers new and shared mutations in SARS-CoV-2 variants as a result of directional and convergent evolution</a>
|
||||
</div></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
||||
<ul>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>BREATHE: Virtual Self-management for Long COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Other: BREATHE<br/><b>Sponsor</b>: <br/>
|
||||
University of Calgary<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: casirivimab+imdevimab<br/><b>Sponsor</b>: <br/>
|
||||
Regeneron Pharmaceuticals<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>JINZHEN for Treatment of Mild to Moderate COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: JINZHEN Granules for Oral Solution; Drug: Placebo<br/><b>Sponsor</b>: Lianyungang Kanion Group, Ltd.<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: Apixaban<br/><b>Sponsors</b>: <br/>
|
||||
Scotmann Pharmaceuticals; Rawalpindi Medical College<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19 in Pakistan</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Other: Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)<br/><b>Sponsors</b>: The Allergy and Asthma Institute, Pakistan; University of Edinburgh<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Validation of Breath Analyser Tests for Diagnosis of COVID-19.</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Diagnostic Test: Breath Sample analysis<br/><b>Sponsor</b>: Tera Group<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Biological: Experimental Group<br/><b>Sponsor</b>: <br/>
|
||||
Sinovac Biotech Co., Ltd<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate Safety & Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: SARS-CoV-2 DNA Vaccine; Biological: Matching placebo<br/><b>Sponsors</b>: The University of Hong Kong; Immuno Cure 3 Limited<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol</strong> - <b>Conditions</b>: COVID-19; SARS-CoV2 Infection<br/><b>Interventions</b>: Biological: Ad5-triCoV/Mac; Biological: ChAd-triCoV/Mac<br/><b>Sponsors</b>: McMaster University; Canadian Institutes of Health Research (CIHR)<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Homeopathic Treatment of Post-acute COVID-19 Syndrome</strong> - <b>Condition</b>: Post-acute Covid-19 Syndrome<br/><b>Interventions</b>: Drug: Homeopathic Medication; Other: Placebo<br/><b>Sponsors</b>: Southwest College of Naturopathic Medicine; Samueli Institute for Information Biology<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effect of PBM on Functional Capacity and Fatigability in Post Covid-19 Elderly</strong> - <b>Condition</b>: Post Covid-19 Elderly<br/><b>Interventions</b>: Radiation: photobiomodulation; Other: placebo intervention by photobiomodulation device<br/><b>Sponsor</b>: Cairo University<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effectiveness of Interactive Voice Response for COVID-19 Vaccination Training in the Democratic Republic of the Congo</strong> - <b>Conditions</b>: COVID-19 Vaccine Knowledge; COVID-19 Vaccine Beliefs and Behaviors<br/><b>Interventions</b>: Behavioral: COVID-19 Vaccine IVR Training; Behavioral: Control Condition<br/><b>Sponsors</b>: <br/>
|
||||
Stanford University; Viamo<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study</strong> - <b>Condition</b>: COVID-19 Pandemic<br/><b>Interventions</b>: Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01); Biological: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)<br/><b>Sponsor</b>: Livzon Pharmaceutical Group Inc.<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)</strong> - <b>Condition</b>: Post-Acute Sequelae of COVID-19<br/><b>Interventions</b>: Device: Active tDCS; Device: Sham tDCS<br/><b>Sponsor</b>: Massachusetts General Hospital<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Effect Of Music On Compliance Of Patients İn COVİD-19 Intensive Care Unit With CPAP Device</strong> - <b>Conditions</b>: COVID-19; COVID-19 Acute Respiratory Distress Syndrome<br/><b>Intervention</b>: Device: Listening to music with a bluetooth headset to patients receiving CPAP support<br/><b>Sponsors</b>: SÜMEYYE BİLGİLİ; Ataturk University<br/><b>Recruiting</b></p></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
||||
<ul>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Harnessing stress granule formation by small molecules to inhibit the cellular replication of SARS-CoV-2</strong> - We identified small-molecule enhancers of cellular stress granules by observing molecular crowding of proteins and RNAs in a time-dependent manner. Hit molecules sensitized the IRF3-mediated antiviral mechanism in the presence of poly(I:C) and inhibited the replication of SARS-CoV-2 by inducing stress granule formation. Thus, modulating multimolecular crowding can be a promising strategy against SARS-CoV-2.</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sensing of cytoplasmic chromatin by cGAS activates innate immune response in SARS-CoV-2 infection</strong> - The global coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive-sense RNA virus. How the host immune system senses and responds to SARS-CoV-2 infection remain largely unresolved. Here, we report that SARS-CoV-2 infection activates the innate immune response through the cytosolic DNA sensing cGAS-STING pathway. SARS-CoV-2 infection induces the cellular level of 2’3’-cGAMP associated with STING activation. cGAS…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants</strong> - The current COVID-19 pandemic has heavily burdened the global public health system and may keep simmering for years. The frequent emergence of immune escape variants have spurred the search for prophylactic vaccines and therapeutic antibodies that confer broad protection against SARS-CoV-2 variants. Here we show that the bivalency of an affinity maturated fully human single-domain antibody (n3113.1-Fc) exhibits exquisite neutralizing potency against SARS-CoV-2 pseudovirus, and confers effective…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Auranofin: Past to Present, and repurposing</strong> - Auranofin (AF), a gold compound, has been used to treat rheumatoid arthritis (RA) for more than 40 years; however, its mechanism of action remains unknown. We revealed that AF inhibited the induction of proinflammatory proteins and their mRNAs by the inflammatory stimulants, cyclooxygenase-2 and inducible nitric oxide synthase, and their upstream regulator, NF-κB. AF also activated the proteins peroxyredoxin-1, Kelch-like ECH-associated protein 1, and NF-E2-related factor 2, and inhibited…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Methotrexate as a safe immunosuppressive agent during the COVID-19 pandemic</strong> - CONCLUSION: The present findings demonstrated that methotrexate does not predispose patients to severe COVID-19; on the contrary, patients taking methotrexate may experience a milder disease, possibly due to their reduced severe inflammatory reactions as a result of inhibited TNFα, lowered IL6, and increased T regulatory cells. According to these findings, methotrexate appears to be a suitable treatment option for patients who need immunosuppressive medications during the COVID-19 pandemic.</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>An airway organoid-based screen identifies a role for the HIF1alpha-glycolysis axis in SARS-CoV-2 infection</strong> - It is urgent to develop disease models to dissect mechanisms regulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we derive airway organoids from human pluripotent stem cells (hPSC-AOs). The hPSC-AOs, particularly ciliated-like cells, are permissive to SARS-CoV-2 infection. Using this platform, we perform a high content screen and identify GW6471, which blocks SARS-CoV-2 infection. GW6471 can also block infection of the B.1.351 SARS- CoV-2 variant. RNA…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>New tale on LianHuaQingWen: IL6R/IL6/IL6ST complex is a potential target for COVID-19 treatment</strong> - LianHuaQingWen (LHQW) improves clinical symptoms and alleviates the severity of COVID-19, but the mechanism is unclear. This study aimed to investigate the potential molecular targets and mechanisms of LHQW in treating COVID-19 using a network pharmacology-based approach and molecular docking analysis. The main active ingredients, therapeutic targets of LHQW, and the pathogenic targets of COVID-19 were screened using the TCMSP, UniProt, STRING, and GeneCards databases. According to the…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L</strong> - Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is a promising drug target for novel antivirals against SARS-CoV-2. The marine natural product gallinamide A and several synthetic analogues were identified as potent inhibitors of cathepsin L with IC(50) values in the picomolar range. Lead molecules possessed selectivity over other cathepsins and alternative host proteases involved in viral entry. Gallinamide A directly interacted with cathepsin L in cells…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Dasabuvir Inhibits Human Norovirus Infection in Human Intestinal Enteroids</strong> - Human noroviruses (HuNoVs) are acute viral gastroenteritis pathogens that affect all age groups, yet no approved vaccines and drugs to treat HuNoV infection are available. In this study, we screened an antiviral compound library to identify compound(s) showing anti-HuNoV activity using a human intestinal enteroid (HIE) culture system in which HuNoVs are able to replicate reproducibly. Dasabuvir (DSB), which has been developed as an anti-hepatitis C virus agent, was found to inhibit HuNoV…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study</strong> - COVID-19 (Coronavirus disease of 2019) pandemic is one of the largest health threats the planet has faced in recent decades. Efforts are being continuously made to design a viable drug or a vaccine. Several natural and synthetic molecules are under study for their potency to inhibit viral replication. In order to emphasize the importance of microbial-based natural components in antiviral drug discovery, an attempt has been made through this study to find potential inhibitors for SARS-CoV-2…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Rapid inactivation of SARS-CoV-2 with LED irradiation of visible spectrum wavelengths</strong> - Difficulty in controlling SARS-CoV-2 transmission made the ability to inactivate viruses in aerosols and fomites to be an important and attractive risk reduction measure. Evidence that light frequencies have the ability to inhibit microorganisms has already been reported by many studies which, however, focused on ultraviolet (UV) wavelengths, which are known to induce potential injury in humans. In the present study, the effect on suspensions of SARS-CoV-2 of a Light Emitting Diode (LED) device…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Potential Dietary Interventions for COVID-19 Infection Based on the Gut-Immune Axis: An Update Review on Bioactive Component of Macronutrients</strong> - Recently emerged coronavirus, known as SARS-CoV-2 or Covid-19 is considered as a serious threat for human health. Due to unavailable specific drugs for this virus, there is an urgent need for supportive cares. Epigenetic immune boosting approaches and developing anti-inflammatory agents by gut-associated bioactive macronutrients can be plausible protective cares for COVID-19. Suitable intake of bioactive macronutrients including prebiotics, fatty acids, proteins and branched-chain amino acids…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>In silico identification of potential inhibitors against main protease of SARS-CoV-2 6LU7 from Andrographis panniculata via molecular docking, binding energy calculations and molecular dynamics simulation studies</strong> - CONCLUSION: In conclusion, findings of the current study suggest that selected diterpenoids were predicted to be the significant phytonutrient-based inhibitor against SARS-CoV-2 6LU7 (M^(pro)). However, preclinical and clinical trials are needed for the further scientific validation before use.</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Broad spectrum antiviral nucleosides-Our best hope for the future</strong> - The current focus for many researchers has turned to the development of therapeutics that have the potential for serving as broad-spectrum inhibitors that can target numerous viruses, both within a particular family, as well as to span across multiple viral families. This will allow us to build an arsenal of therapeutics that could be used for the next outbreak. In that regard, nucleosides have served as the cornerstone for antiviral therapy for many decades. As detailed herein, many nucleosides…</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hemin as a novel candidate for treating COVID-19 via heme oxygenase-1 induction</strong> - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease-19 (COVID-19). More than 143 million cases of COVID-19 have been reported to date, with the global death rate at 2.13%. Currently, there are no licensed therapeutics for controlling SARS-CoV-2 infection. The antiviral effects of heme oxygenase-1 (HO-1), a cytoprotective enzyme that inhibits the inflammatory response and reduces oxidative stress, have been investigated in several viral…</p></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
||||
<ul>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Anti-SARS-CoV-2 antibodies and uses thereof I</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU339290405">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Anti-SARS-CoV-2 antibodies and uses thereof II</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU339290406">link</a></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>휴대용 자화 육각수물 발생기</strong> - 본인의 발명은, 사람의 신체에서 육각수물 생성에는 한계가 있으며, 동맥혈관, 정맥혈관 내부 혈액은 수분이 약 90% 이며, 건강한 성인이면, 육각수 물은 약 62% 이며, COVID-19 환자, 사고의 부상, 17만개의 질병, 질환으로 조직세포가 손상되면 자기 신체수복을 위해서 육각수 물을 평소보다 많이 흡수 하면서 동반 산소부족 상태가 되며, 육각수물 보충 없이 산소 호흡기를 사용하면 심각한 후유증이 발병 할 수 있다.</p></li>
|
||||
</ul>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">육각수물 부족 상태를 해결하기 위해서, 객관적인 과학적으로 네오디뮴(원자번호 = 60) 3.000 가우스의 자기장을 이용하여서 육각수 물을 62% ~ 80% 이상, 상시 유지 시켜주는 제조 방법이며, 휴대용으로 항시 착용 가능하다. 결론은 COVID-19, 질병, 질환의 근본적인 원인은, 육각수물 부족 상태가 되면 동반 산소 부족 상태가 되면서, 염증 -> 통증 -> 극심한 통증 -> 석회화, 섬유화, 암 까지 발병 한다. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=KR338655754">link</a></p>
|
||||
<ul>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>휴대용 자화 육각수물 발생기</strong> - 본인의 발명은, 사람의 신체에서 육각수 생성에는 한계가 있으며, 동맥혈관, 정맥혈관 내부 혈액은 수분이 90% 이며, 육각수물은 약 62% 이며, COVID-19, 사고 부상, 질병, 질환으로 조직세포가 손상되면 자기 신체수복을 위해서 육각수물을 평소보다 많이 흡수하면서 산소부족 상태가 되며, 육각수 보충 없이 산소호흡기를 사용하면 심각한 후유증이 발병 할 수 있다 육각수물 부족 상태를 해결하기 위해서, 객관적인 과학적으로 네오디뮴(원자번호 = 60) 3.000 가우스의 자기장을 이용하여서 육각수물을 62% ~ 80% 상시 유지 시켜주는 제조 방법이며, 휴대용으로 항시 착용 가능하다. 결론은 COVID-19, 질병, 질환의 근본적인 원인은, 육각수물 부족 상태가 되면 동반 산소 부족 상태가 되면서, 염증 -> 통증 -> 극심한 통증 -> 석회화, 섬유화, 암 까지 발병 한다. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=KR338650904">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>用于检测新冠病毒的配对抗体及其应用</strong> - 本发明涉及一种用于检测新冠病毒的配对抗体及其应用，其包括第一检测抗体和第二检测抗体；第一检测抗体具有如SEQ ID NO:1~3所示的轻链互补决定区，以及如SEQ ID NO:4~6所示的重链互补决定区，第二检测抗体具有如SEQ ID NO:7~9所示的轻链互补决定区，以及如SEQ ID NO:10~12所示的重链互补决定区。本发明筛选得到具有上述互补决定区序列的配对抗体，其识别N蛋白的不同表位，且由于两种抗体识别的是N蛋白非核酸结合区域，不会受核酸负电荷干扰，对核酸抗原表现出了兼容性，具有较好的稳定性，同时上述配对抗体具有较高的亲和力，病毒N蛋白检测灵敏度高。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN339127990">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>抗KL-6双特异性抗体及基因、重组载体、药物、试剂盒</strong> - 本发明公开了抗KL‑6双特异性抗体或其变体、或其功能性片段，所述抗KL‑6双特异性抗体或其变体、或其功能性片段包括抗PTS域和抗SEA域，所述抗PTS域的重链可变区的CDR1、CDR2和CDR3分别具有SEQ ID NO.1~3所示的氨基酸序列。本发明还提供了基因、重组载体、药物、试剂盒。本发明的抗KL‑6双特异性抗体或其变体、或其功能性片段用于与KL‑6蛋白特异性结合，基因、重组载体用于抗KL‑6双特异性抗体的制备，药物用于治疗KL‑6蛋白引起的相关疾病，试剂盒用于KL‑6蛋白的定量检测。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN338723529">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>基于决策树模型与逻辑回归模型组合的感染筛查方法</strong> - 本发明公开了一种基于决策树模型与逻辑回归模型组合的感染筛查方法，其检测操作方便，可提高感染筛查准确性，该方法基于生命体征监护仪实现，生命体征监护仪与远程数据服务平台通信连接，远程数据服务平台依据临床数据进行感染筛查，该方法包括：通过生命体征监护仪检测获取用户临床数据，将临床数据随机划分为训练集、测试集，将训练集均分为两份：训练集A、训练集B，基于训练集A构建决策树模型，同时，对训练集A进行特征选择，将关键特征向量作为已构建的决策树模型的输入，获取新构造特征向量，基于组合特征向量，构造逻辑回归模型，基于决策树模型和逻辑回归模型组合，对测试集进行预测分类，获取分类结果。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN339127711">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>病毒中和抗体与非中和抗体联合检测方法、检测卡及应用</strong> - 一种病毒中和抗体与非中和抗体联合检测方法、检测卡及其应用，通过病毒受体结合蛋白夹心法原理检测中和抗体，其为通过提前设置病毒受体结合蛋白和能阻断中和抗体与其结合的作为配体的蛋白所形成的复合物，将靶向受体蛋白的非中和抗体提前捕获，保证后续通过夹心法检测中和抗体的特异性。解决了现有技术中中和抗体检测灵敏度低、特异性差以及不能区分中和抗体与非中和抗体的问题，提供了一种简便、快速、灵敏度高、特异性高的病毒中和抗体与非中和抗体联合检测方法、检测卡及其应用。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN338613501">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>扩增△500-532的SARS-CoV-2 Nsp1基因的引物对及其检测方法</strong> - 本发明公开了一种扩增Δ500‑532的SARS‑CoV‑2 Nsp1基因的引物对及其检测方法。引物对的具体序列如SEQ ID NO.1和SEQ ID NO.2所示，其检测方法为：采用引物对对SARS‑CoV‑2 Nsp1基因进行PCR，对PCR产物进行变性退火后，加入T7EI内切酶孵育，再进行PCR扩增，并判断是否存在Δ500‑532的SARS‑CoV‑2 Nsp1基因。本发明可简便快捷的区分出SARS‑CoV‑2 Nsp1基因突变型和野生型。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN339334235">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>多肽及其在新型冠状病毒检测中的应用</strong> - 本发明涉及生物医学领域，具体而言，涉及一种多肽及其在新型冠状病毒检测中的应用。所述多肽包括如下部分：S——Linker——N——avi‑tag。通过经过优化的刚性linker序列把S蛋白和N蛋白串联起来，使得这两个蛋白即具备相对独立的空间构象，又增加了许多优势表位，很大程度上提高了灵敏度和信号值；此外，融合蛋白引入Avi‑tag，使得重组蛋白可以通过固定的位点被固相化，降低包被过程所带来的空间位阻的影响。由此，该多肽能够达到很高的灵敏度和特异性，并且不易发生漏检。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN339334229">link</a></p></li>
|
||||
</ul>
|
||||
|
||||
|
||||
<script>AOS.init();</script></body></html>
|
||||
File diff suppressed because it is too large
Load Diff
File diff suppressed because one or more lines are too long
Loading…
Reference in New Issue